This has been a disruptive year for the life sciences industry. While the COVID-19 pandemic impacted thousands of clinical trials across the globe, bringing many to a staggering halt. On the other hand, we saw the industry rising to the occasion, and accelerating COVID-19 vaccine trials, with vaccines being approved in less than a year. The industry transitioned from a technologically averse, inwards looking model, to working in an agile and a collaborative manner. Digital resiliency was what mattered. Innovation, driven by technology adoption, took center stage.

With the ongoing momentum from the digital evolution underway, what new developments should we expect this year?